Bryostatin 1 enhances lymphokine activated killer sensitivity and modulates the β1 integrin profile of cultured human tumor cells

P. Correale, M. Caraglia, A. Fabbrocini, R. Guarrasi, S. Pepe, V. Patella, G. Marone, A. Pinto, A. R. Bianco, P. Tagliaferri

Research output: Contribution to journalArticlepeer-review

Abstract

Bryostatin 1 interferes with protein kinase C (PKC) signaling which is involved in the activation of human and murine cytotoxic T lymphocytes, and in the growth and differentiation of tumor cells. Bryostatin 1 has immuno-modulating and antitumor properties as demonstrated by preclinical and clinical studies. Here we report that bryostatin 1 increases the susceptibility to lymphokine activated killers and modifies the pattern of β1 integrin expression of human tumor cells. On the basis of these results the use of bryostatin 1 in combination with immunostimulating cytokines such as interleukin-2 in the treatment of human cancer is suggested.

Original languageEnglish
Pages (from-to)285-290
Number of pages6
JournalAnti-Cancer Drugs
Volume6
Issue number2
Publication statusPublished - 1995

Keywords

  • β integrins
  • Bryostatin 1
  • Human tumor cells
  • Lymphokine activated killer

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research
  • Oncology

Fingerprint

Dive into the research topics of 'Bryostatin 1 enhances lymphokine activated killer sensitivity and modulates the β1 integrin profile of cultured human tumor cells'. Together they form a unique fingerprint.

Cite this